Inhibrx Biosciences (NASDAQ:INBX) (NASDAQ: INBX) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel protein-based therapeutics for oncology, rare genetic disorders and immunology. Founded in 2007 and headquartered in La Jolla, California, Inhibrx leverages its proprietary Nanofitin® and Decafectin® molecular scaffolds alongside a suite of antibody-derived platforms to engineer next-generation biologics with improved selectivity, potency and manufacturability. The company’s R&D operations in San Diego focus on advancing candidates from preclinical validation through first-in-human studies, with an emphasis on modular design that can be rapidly optimized for diverse targets.
Inhibrx’s pipeline includes multiple clinical assets across oncology and rare disease indications. Lead candidates such as INBRX-109, a tetravalent EGFR-targeted agent, and INBRX-101, an enzyme replacement therapy for X-linked myotubular myopathy, are designed to address unmet medical needs by combining high target affinity with favorable pharmacokinetic profiles. Additional programs are advancing through IND-enabling studies, spanning immune checkpoint modulators and cytokine neutralizers. The company also pursues strategic collaborations and licensing agreements to extend its reach into global markets and leverage complementary expertise.
While primarily focused on the U.S. market, Inhibrx has initiated partnerships to facilitate clinical research in Europe and Asia, aiming to broaden patient access upon regulatory approval. The company maintains a network of academic and industry collaborators to support translational research and streamline manufacturing processes. Inhibrx’s leadership team is spearheaded by co-founder and Chief Executive Officer Vijayarama P. Vadlamudi, Ph.D., whose background in protein engineering underpins the company’s scientific vision. The executive team also includes seasoned professionals in clinical development, regulatory affairs and commercial strategy.
Since completing its initial public offering in 2020, Inhibrx has steadily expanded its technological capabilities and clinical footprint. With a clear focus on innovative protein architectures, the company aims to deliver differentiated therapies that improve outcomes for patients facing challenging oncologic and genetic conditions. As Inhibrx advances its most promising candidates through late-stage studies, it seeks to collaborate with global partners to bring transformative treatments from bench to bedside.
